Drug Interaction With Sunitinib and the Evidence of Therapeutic Drug Monitoring: A Case Report and Review of the Literature

被引：2
作者：
Bertolaso, Pauline [1 ]
Gross-Goupil, Marine [1 ]
Molimard, Mathieu [2 ]
Cochin, Valerie [1 ,3 ]
Ravaud, Alain [1 ,3 ]
Daste, Amaury [1 ]
机构：
[1] CHU Bordeaux, Univ Hosp, Hop St Andre, Dept Med Oncol, Bordeaux, France
[2] Univ Bordeaux, INSERM, U657, Pharmacol Dept, Bordeaux, France
[3] Univ Bordeaux, Bordeaux, France
来源：
CLINICAL GENITOURINARY CANCER | 2017年 / 15卷 / 05期
关键词：
Metastatic renal cell carcinoma; Pharmacokinetics; Therapeutic drug monitoring; TKI; VEGF-R targeted therapy; RENAL-CELL CARCINOMA; CANCER-PATIENTS; PHARMACOKINETICS; THERAPIES; SAFETY; RISK;
D O I：
10.1016/j.clgc.2017.05.004
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Sunitinib has demonstrated efficacy, notably in metastatic renal cell carcinoma, but has also induced frequent diverse adverse events and has a large panel of drug interaction, notably with CYP 450. Sunitinib needs close monitoring for frail patients with high risk of side effects or drug interaction. We describe a successful therapeutic pharmaco-kinetic drug monitoring plan for a patient with a cardiac transplant presenting with metastatic renal cell carcinoma while adapting the dose of sunitinib. (C) 2017 Elsevier Inc. All rights reserved.
引用
收藏
页码：E885 / E887
页数：3
相关论文
共 20 条
  • [1] Drug interactions with sunitinib
    Bilbao-Meseguer, Idoia
    San Jose, Begona
    Lopez-Gimenez, Leocadio R.
    Gil, Maria A.
    Serrano, Laura
    Castano, Mikel
    Sautua, Saioa
    De Basagoiti, Amaya
    Belaustegui, Ainhoa
    Baza, Beatriz
    Baskaran, Zurine
    Bustinza, Alazne
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2015, 21 (01) : 52 - 66
  • [2] Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    Chu, Tammy F.
    Rupnick, Maria A.
    Kerkela, Risto
    Dallabrida, Susan M.
    Zurakowski, David
    Nguyen, Lisa
    Woulfe, Kathleen
    Pravda, Elke
    Cassiola, Flavia
    Desai, Jayesh
    George, Suzanne
    Morgan, Jeffrey A.
    Harris, David M.
    Ismail, Nesreen S.
    Chen, Jey-Hsin
    Schoen, Frederick J.
    Van den Abbeele, Annick D.
    Demetri, George D.
    Force, Thomas
    Chen, Ming Hui
    [J]. LANCET, 2007, 370 (9604) : 2011 - 2019
  • [3] Benefit of therapeutic drug monitoring to disclose pharmacokinetic interaction between sunitinib and calcium channel blocker
    Da Silva, F.
    Thomas-Schoemann, A.
    Huillard, O.
    Goldwasser, F.
    Blanchet, B.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 (08) : 1651 - 1652
  • [4] Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer
    Faivre, S
    Delbaldo, C
    Vera, K
    Robert, C
    Lozahic, S
    Lassau, N
    Bello, C
    Deprimo, S
    Brega, A
    Massimini, G
    Armand, JP
    Scigalla, P
    Raymond, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (01) : 25 - 35
  • [5] Evidence for Therapeutic Drug Monitoring of Targeted Anticancer Therapies
    Gao, Bo
    Yeap, Shang
    Clements, Arthur
    Balakrishnar, Bavanthi
    Wong, Mark
    Gurney, Howard
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) : 4017 - 4025
  • [6] The Frequency and Severity of Cardiovascular Toxicity From Targeted Therapy in Advanced Renal Cell Carcinoma Patients
    Hall, Philip S.
    Harshman, Lauren C.
    Srinivas, Sandy
    Witteles, Ronald M.
    [J]. JACC-HEART FAILURE, 2013, 1 (01) : 72 - 78
  • [7] Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis
    Houk, Brett E.
    Bello, Carlo L.
    Poland, Bill
    Rosen, Lee S.
    Demetri, George D.
    Motzer, Robert J.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (02) : 357 - 371
  • [8] Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function
    Khosravan, Reza
    Toh, Melvin
    Garrett, May
    La Fargue, JoAnn
    Ni, Grace
    Marbury, Thomas C.
    Swan, Suzanne K.
    Lunde, Norman M.
    Bello, Carlo L.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (04) : 472 - 481
  • [9] Sunitinib for metastatic renal cell cancer patients: observational study highlighting the risk of important drug-drug interactions
    Kruse, V.
    Somers, A.
    Van Bortel, L.
    De Both, A.
    Van Belle, S.
    Rottey, S.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2014, 39 (03) : 259 - 265
  • [10] Lainakis G, 2009, CLIN NEPHROL, V72, P73
12